Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: A 12 week multicenter, double blind, dose response study versus placebo and diclofenac

Journal of Rheumatology

Volumn 29, Issue 3, 2002, Pages 436-446

  Furst, Daniel E ^a   Kolba, Karen S ^a   Fleischmann, Roy ^a   Silverfield, Joel ^a   Greenwald, Maria ^a   Roth, Sanford ^a   Hall, David B ^a   Roszko, Paul J ^a  

^a Virginia Mason Medical Clinic   (United States)

Author keywords

Cyclooxygenase 2; Drug dose response relationship; Meloxicam; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYDROXYCHLOROQUINE; MELOXICAM; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOCTOR PATIENT RELATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOENZYMES; LIVER FUNCTION TESTS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLACEBOS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 0036197663     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. The clinical features of rheumatoid arthritis
2. Remodelling the pyramid: The therapeutic target of rheumatoid arthritis
3. New approaches to the management of rheumatoid arthritis
4. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
5. Differential inhibition of COX-1 and COX-2 by NSAIDs: A summary of results obtained using various test systems
6. Selective inhibition of human cyclo-oxygenase-2 by meloxicam
7. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
8. Insight into the structural basis of selective cyclooxygenase-2 inhibition
9. Bleeding time and platelet function in normal volunteers receiving meloxicam
10. Safety and efficacy of meloxicam in the treatment of osteoarthritis: A 12-week, double-blind, multiple-dose, placebo-controlled trial
11. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee
12. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
13. Improvement in gastrointestinal tolerability of the selective cyclooxygenase COX-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large scale evaluation of COX inhibition therapies (SELECT) trial in osteoarthritis
14. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee
15. Meloxicam in osteoarthritis: A six-months, double-blind comparison with diclofenac sodium
16. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee
17. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks NSAID trial
18. Efficacy and safety of meloxicam in patients with rheumatoid arthritis
19. A six-months double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis
20. A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis
21. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis
22. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison with 20 mg piroxicam in patients with rheumatoid arthritis
23. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis